Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel Free FNCH Stock Alerts

Finch Therapeutics Group (FNCH) Competitors

Finch Therapeutics Group logo
$7.30 0.00 (0.00%)
As of 08/14/2026
Compare

FNCH vs. RYM, VERU, KPTI, CPHI, and FLNA

Should you buy Finch Therapeutics Group stock or one of its competitors? Finch Therapeutics Group's main competitors and comparable companies include RYTHM (RYM), Veru (VERU), Karyopharm Therapeutics (KPTI), China Pharma (CPHI), and Cassava Sciences (FLNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Finch Therapeutics Group compare to RYTHM?

RYTHM (NASDAQ:RYM) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Finch Therapeutics Group has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
RYTHM-6.20% -12.57% -2.60%
Finch Therapeutics Group N/A -69.14%-26.92%

6.0% of RYTHM shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

RYTHM has higher revenue and earnings than Finch Therapeutics Group. RYTHM is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RYTHM$17.28M2.62-$33.26M-$10.53N/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

RYTHM has a beta of 9.47, meaning that its stock price is 847% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

In the previous week, RYTHM had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for RYTHM and 1 mentions for Finch Therapeutics Group. RYTHM's average media sentiment score of 1.47 beat Finch Therapeutics Group's score of 0.00 indicating that RYTHM is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RYTHM
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Finch Therapeutics Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RYTHM
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

RYTHM beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Veru?

Finch Therapeutics Group (NASDAQ:FNCH) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Veru has higher revenue and earnings than Finch Therapeutics Group. Veru is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Veru$16.89M2.76-$22.73M-$0.89N/A

Veru's return on equity of -47.58% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Veru N/A -47.58%-35.83%

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Veru has a consensus price target of $24.50, suggesting a potential upside of 797.44%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Veru
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Veru has a beta of -1.15, indicating that its stock price is 215% less volatile than the broader market.

In the previous week, Veru had 7 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 8 mentions for Veru and 1 mentions for Finch Therapeutics Group. Veru's average media sentiment score of 0.95 beat Finch Therapeutics Group's score of 0.00 indicating that Veru is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Finch Therapeutics Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veru
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Veru beats Finch Therapeutics Group on 10 of the 14 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Karyopharm Therapeutics?

Finch Therapeutics Group (NASDAQ:FNCH) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Finch Therapeutics Group has higher earnings, but lower revenue than Karyopharm Therapeutics. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Karyopharm Therapeutics$146.07M0.31-$196.04M-$15.09N/A

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Karyopharm Therapeutics had 10 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 11 mentions for Karyopharm Therapeutics and 1 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.03 indicating that Finch Therapeutics Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Finch Therapeutics Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Karyopharm Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 469.31%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Karyopharm Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Finch Therapeutics Group has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Karyopharm Therapeutics -153.28%N/A -144.95%

Summary

Karyopharm Therapeutics beats Finch Therapeutics Group on 9 of the 16 factors compared between the two stocks.

How does Finch Therapeutics Group compare to China Pharma?

China Pharma (NYSE:CPHI) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Finch Therapeutics Group had 1 more articles in the media than China Pharma. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company Overall Sentiment
China Pharma Neutral
Finch Therapeutics Group Neutral

21.8% of Finch Therapeutics Group shares are owned by institutional investors. 6.4% of China Pharma shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Finch Therapeutics Group has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
China Pharma-85.56% -63.93% -31.42%
Finch Therapeutics Group N/A -69.14%-26.92%

China Pharma has higher revenue and earnings than Finch Therapeutics Group. China Pharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Pharma$3.99M11.47-$3.08M-$0.55N/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

China Pharma has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Summary

Finch Therapeutics Group beats China Pharma on 7 of the 11 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Cassava Sciences?

Finch Therapeutics Group (NASDAQ:FNCH) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, meaning that its share price is 170% less volatile than the broader market.

In the previous week, Cassava Sciences had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for Finch Therapeutics Group. Cassava Sciences' average media sentiment score of 0.93 beat Finch Therapeutics Group's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Finch Therapeutics Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cassava Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 447.47%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cassava Sciences is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Cassava SciencesN/AN/A-$90.97M-$0.87N/A

Cassava Sciences' return on equity of -58.78% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Cassava Sciences N/A -58.78%-36.74%

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cassava Sciences beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNCH vs. The Competition

Export
MetricFinch Therapeutics GroupPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11.72M$11.80B$7.03B$13.07B
Dividend YieldN/A2.70%2.57%10.64%
P/E Ratio-0.83779.99271.2625.40
Price / SalesN/A748.58622.95105.59
Price / CashN/A89.0475.7053.27
Price / Book0.5111.6012.926.21
Net Income-$74.75M$2.77B$3.45B$347.71M
7 Day PerformanceN/A0.14%1.16%1.08%
1 Month PerformanceN/A0.65%2.17%1.87%
1 Year Performance-42.52%145.68%62.38%20.79%

Finch Therapeutics Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNCH
Finch Therapeutics Group
N/A$7.30
flat		N/AN/A$11.72MN/AN/A190
RYM
RYTHM
1.136 of 5 stars		$21.15
-4.8%		N/AN/A$46.38M$17.28MN/A140
VERU
Veru
2.1998 of 5 stars		$2.70
flat		$24.50
+807.4%		-24.0%$45.86M$16.89MN/A230
KPTI
Karyopharm Therapeutics
2.7887 of 5 stars		$2.00
+0.5%		$11.50
+475.0%		-65.9%$45.33M$151.12MN/A380
CPHI
China Pharma
N/A$1.11
+1.4%		N/A-21.0%$44.78M$3.99MN/A250

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FNCH) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The Greatest Wealth Transfer Since the Internet Boom Just Started
Wall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...
Altimetry | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel